The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K–Akt Pathways

The targeting of the Mitogen-Activated Protein Kinase (MAPK) signalling pathway in melanoma improves the prognosis of patients harbouring the V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) mutation. However, a fraction of these patients may experience tumour progression due to resistance to t...

Descripción completa

Detalles Bibliográficos
Autores principales: Candido, Saverio, Salemi, Rossella, Piccinin, Sara, Falzone, Luca, Libra, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950976/
https://www.ncbi.nlm.nih.gov/pubmed/35335966
http://dx.doi.org/10.3390/pharmaceutics14030590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8950976/
https://www.ncbi.nlm.nih.gov/pubmed/35335966
http://dx.doi.org/10.3390/pharmaceutics14030590

Ejemplares similares